Merck Patent Gmbh

Andrew Bender

Daigen Xu

Eike Staub

Ilhan Celik

Miriam Urban

Eileen Samy

Yin Wu

Richard Dana Caldwell

Lesley Liu-Bujalski

Sabine Raab

Roland Grenningloh

Georgianna Higginbotham

Sabine Raab-Westphal

Albertina Pereira

Georgianna Varrone

A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders

The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting &#x3b1;v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.

The present invention relates to BTK occupancy assays.

Assays for BTK inhibitors

Growing community of inventors

Reading, MA, United States of America

Andrew Bender